FLT3 and acute myeloid leukemia: Preclinical data show that the combination of gilteritinib with VEN synergistically enhances apoptosis and reduces viability in both AZA/VEN-resistant cell lines and primary patient samples, even in wild-type FLT3 AML, by decreasing MCL1 levels [74].